This Life Sciences Dynamic Talks session takes a close look at the future of life sciences pricing strategies in the “new normal.” From non-traditional blocs to Brexit and the rise of net price transparency, a number of global trends exacerbated by COVID-19 are increasingly affecting pricing for pharma.
In this session, EVERSANA’s Alan Crowther identifies recent and upcoming changes to the global pharmaceutical market around launch sequencing and net price transparency and discusses how these changes will affect product launches. He also highlights how companies can prepare for future launches in this new and shifting market.
NAVLIN Price & Access Data is a powerful competitor intelligence tool that provides near real-time updates to drug price (list / net), reimbursement, tender and cost of treatment information at the indication level. Our…